68. Zangari M, Siegel E, Barlogie B, et al.: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100:1168-1171, 2002.

69. Zangari M, Anaissie E, Barlogie B, et al.: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615, 2001.

70. Hussein M, Elson P, Tso E, et al.: Doxil (D), Vincristine (V), Decadron (d) and Thalidomide (T) (DVd-T)for Relpased/Refractory Multiple Myeloma (RMM). Blood 100(suppl): 2002.

71. Comenzo R, Hassoun H, Reich L, et al.: Doxorubicin and Dexamethasone followed by Thalidomide and Dexamethasone as Initial Therapy for Symptomatic Patients with Multiple Myeloma. Washington, DC: American Society of Hematology; 2003.

72. Corso A, Lorenzi A, Terulla V, et al.: Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 83:588-591, 2004.

73. Zangari M, Barlogie B, Anaissie E, et al.: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126:715-721, 2004.

74. Richardson PG, Schlossman RL, Weller E, et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002.

This page intentionally left blank

0 0

Post a comment